Evidence map›Paper›PMID 42539219›Full record

ArticlebioRxiv : the preprint server for biology2026

Cyclic immunofluorescence platform using photocleavable linkers for direct antibody labeling enables cancer phenotyping.

Amanda Zucker, Cam Nguyen, Frederik Brøndsted, Jocelyn A Jones, Gauri S Malankar, Taelor J Ekstrom, Cody Rounds, Divya Ravi, Shaun M Goodyear, Adel Kardosh and 3 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amanda ZuckerDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University (OHSU), Portland, OR, 97201.ORCID 0000-0002-9283-7072
Cam NguyenPortland State University, Portland, Oregon, 97201, USA.
Frederik BrøndstedDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USA.ORCID 0000-0001-8402-2562
Jocelyn A JonesDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USA.ORCID 0000-0002-3836-6433
Gauri S MalankarDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USA.
Taelor J EkstromDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University (OHSU), Portland, OR, 97201.ORCID 0000-0001-9829-9570
Cody RoundsDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USA.ORCID 0009-0003-2586-2731
Divya RaviDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University (OHSU), Portland, OR, 97201.ORCID 0009-0005-4253-2069
Shaun M GoodyearKnight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.ORCID 0000-0003-0217-0890
Adel KardoshKnight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.ORCID 0000-0002-6241-4896
Melissa H WongDepartment of Cell, Developmental and Cancer Biology, Oregon Health & Science University (OHSU), Portland, OR, 97201.ORCID 0000-0002-5127-279X
Lei G WangDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USA.ORCID 0000-0002-0664-2704
Summer L GibbsDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USA.ORCID 0000-0001-8077-1582

Funding

High Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0M
Ultra-high content analyses of circulating and solid tumor cells: A diagnostic reference system for disease burdenR44CA250861 · NCI · QUANTITATIVE IMAGING SYSTEMS, LLC · PI NEDERLOF, MICHEL · 2021 to 2023
$1.9M
NCI NIH HHS R44 CA250861NIH HHS S10 OD034224
6 · The paper itself

Abstract

Advances in spatial proteomics through the development of multiplexed immunostaining platforms have facilitated analyses with increasing cellular and molecular granularity. However, currently available approaches are limited by harsh conditions for signal removal, restricting the number of antigens that can be probed in a single specimen without significant alterations to sample quality and structure. Here we present an approach for direct labeling of primary antibodies with fluorophores using a photocleavable linker (PCL) with a polyethylene glycol spacer (PEG) to enable cyclic immunofluorescence (cyCIF) with gentle signal removal conditions. Our innovative approach uses directly labeled primary antibodies to enhance staining specificity and cyclic immunostaining efficiency, while minimizing nonspecific background signal. Additionally, through integration of the PCL, this approach facilitates gentle cleavage of antibody conjugated fluorophore, preserving sample integrity over multiple rounds of staining. Direct PEG-PCL antibody labeling will promote greater multiplexing by minimizing specimen damage and allow for quantitative analyses of cyCIF spatial data. We demonstrate that cyCIF with PEG-PCL conjugated antibodies can be applied across a variety of cancer subtypes to identify and characterize rare neoplastic cell populations in both tumor tissue and fragile peripheral blood specimens.

Indexed as

cyclic immunofluorescence (cyCIF)fluorescent probeshybrid cellsphotocleavable linkers

Identifiers

PMID42539219
PMCPMC13419784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.